What You Should Know:
– Synapticure, a virtual care company focused on neurodegenerative diseases secures $25M in a Series A funding round led by B Capital, the investment includes participation from new investors CommonSpirit Health, CVS Health Ventures, RA Capital Management, and Nexus NeuroTech Ventures, as well as existing investors Google Ventures, Optum Ventures, and Rock Health Capital.
– Founded by individuals with firsthand experience navigating the challenges of neurodegenerative diseases, Synapticure is deeply committed to patient- and caregiver-centric care. The company’s mission is to transform the lives of millions affected by these conditions by providing accessible, comprehensive, and compassionate care.
Addressing the Growing Need for Neurodegenerative Care
Co-founded by patient and caregiver Brian Wallach and Sandra Abrevaya, Synapticure was created to address the unmet needs of patients and caregivers facing Alzheimer’s, Parkinson’s, ALS, Huntington’s Disease, and other neurodegenerative conditions. Since its launch in 2022, Synapticure has rapidly expanded its reach, providing comprehensive virtual care to thousands of patients across the United States.
Transforming Care for Neurodegenerative Diseases
Synapticure is transforming the care landscape for neurodegenerative diseases by:
- Providing timely access to specialists: Offers appointments within two weeks, addressing the long wait times often experienced by patients.
- Delivering comprehensive care: Provides virtual access to neurologists, treatment guidance, clinical trial information, care coordination, and behavioral health support.
- Improving patient outcomes: Leverages AI-powered analytics and clinical research to accelerate diagnosis and optimize treatment plans.
- Reducing the burden on families: Offers support and resources to caregivers managing the complexities of neurodegenerative conditions.
Expanding Access to Care
The funding will enable Synapticure to:
- Expand partnerships: Collaborate with leading healthcare providers and payers to increase access to care.
- Enhance technology platform: Invest in its AI-powered platform to improve diagnosis, treatment, remote monitoring, and support for patients and caregivers.
- Accelerate clinical research: Facilitate patient access to clinical trials and emerging treatments.
- Scale its medical group: Expand its network of providers to meet the growing demand for neurodegenerative care.
“This investment will enable Synapticure to continue to democratize care for people and their families living with neurodegenerative diseases,” said Sandra Abrevaya, caregiver, advocate, co-founder, and CEO of Synapticure. “As a caregiver for the last seven years, I’ve experienced firsthand how overwhelming it can be to carry the weight of someone else’s well-being while navigating the complexities of care and treatment. For too long this struggle has been accepted as just another part of life, but Synapticure refuses to accept that. Synapticure is designed to not only make high-quality care accessible, but to ease the burden on patients and caregivers by providing immediate access to expert neurologists, comprehensive wraparound care, and caregiver support services. With the support of B Capital as well as both new and existing blue-chip investors, I am proud Synapticure works to reach patients in any community across the U.S. living with one of these conditions so they can receive the expert, personalized specialty care they deserve.”
